Sarilumab
Sarilumab is an interleukin-6 (IL-6) receptor blocker in phase III clinical trials for the treatment of rheumatoid arthritis. It was co-developed by Sanofi and Regeneron.
General Information
Update Date：2015-10-10
- Drug Name：
- Sarilumab
- Research Code：
- REGN-88; SAR-153191
- Trade Name：
- MOA：
- Interleukin-6 receptor blocker
- Indication：
- Rheumatoid arthritis
- Status：
- Phase III (Active)
- Company：
- Sanofi (Originator), Regeneron (Originator)
- Sales：
- ATC Code：
Biology Structure
Update Date：2015-10-14
| Type | Whole antibody |
|
| Source | Human | |
| Molecular Formula | C6388H9918N1718O1998S44 | |
| Molecular Weight | 144130 | |
| CAS No. | 1189541-98-7 | |
| Expression System |